health · 3 outlets · 3 linked reports
FDA Approves the First Non-Antipsychotic Drug for Alzheimer's Agitation
AI-assisted: summaries and questions may be incomplete or incorrect. Verify important details with the linked original reporting.
Summary
- On April 30, 2026, the FDA approved Auvelity (dextromethorphan-bupropion) to treat agitation associated with Alzheimer's dementia — the first approved treatment for the condition that isn't an antipsychotic.
- Agitation is one of the most distressing and common symptoms of Alzheimer's, and antipsychotics carry serious safety warnings in dementia patients.
- It adds to a growing 2026 toolkit that includes disease-modifying infusions like Leqembi and Kisunla.
The question
New non-antipsychotic options will meaningfully improve dementia care.
Open this story in Khali
Get Khali on the App Store